|Bid||645.63 x 800|
|Ask||662.89 x 800|
|Day's range||647.54 - 664.85|
|52-week range||492.13 - 747.42|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||10.57|
|Earnings date||03 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||702.05|
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog